Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Redx Pharma Agrees Dishman Collaboration

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
License agreement will allow Dishman to use process technology patented by the Liverpool-based firm.

The early stage drug development company Redx Pharma has announced a license agreement that will allow Dishman Pharmaceuticals & Chemicals to use process technology patented by the Liverpool-based firm.

The deal will see Dishman, which is listed on the Mumbai stock exchange and is a global supplier to the pharmaceutical industry, employ the Redx technology for the synthesis of statins, one of the world’s best selling classes of prescription drugs.

Financial terms were not disclosed but it is anticipated that the deal will generate multi-million dollar revenues for both companies.

Dr Neil Murray, chief executive of Redx Pharma, commented: “This collaboration will create substantial revenues from our intellectual property portfolio and is the first of many deals we look forward to announcing. We are delighted to work with Dishman and pleased to have reached this agreement.”

“We are delighted to be able to offer our customers access to Redx Pharma’s technology and thus create opportunities for the pharmaceutical companies we serve.” commented Christian Dowdeswell, Commercial Director Dishman Group.

Dowdeswell continued, “This deal fits very neatly into Dishman Group’s core principle of investment and innovation and ensures that we can continue to offer high value, high quality products to our customers into the future.”

Redx Pharma is developing a portfolio of new drug candidates across multiple therapeutic areas. These new medicines offer patient benefits that include greater efficacy and fewer side effects.

The drug development programmes are characterized by demonstrably lower risk and greater speed into development - and create licensing opportunities for large pharma companies.

Earlier this year Redx launched its first spin out business, Redx Oncology, and is presently planning a second, Redx Anti-Infectives.

As a global partner for pharmaceutical companies, Dishman has a portfolio of products and development, scale-up and manufacturing services.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pioneering Cancer Research Firm Opens in Liverpool
Launch of Redx Oncology, a new cancer research and development company based in Liverpool.
Tuesday, April 03, 2012
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!